ClinicalTrials.Veeva

Menu

LEAN Project: Weight Loss and Appetite Suppression

T

The Cooper Institute

Status and phase

Completed
Phase 1

Conditions

Weight Loss

Treatments

Drug: PhosphoLean

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a cohort of women in losing weight. Participants taking the supplement will have significantly greater improvement in study outcomes than those taking the placebo.

Full description

Participants will be randomized to either a control or treatment group taking the dietary supplement containing a soy lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and caffeine free Green Tea-derived epigallocathchin gallate (EGCG) whose trade name is PhosphoLean. The outcome is to determine the effects on indices of weight loss and appetite suppression. Participants will return at 6, 12, and 16 weeks for clinical measures.

Sex

Female

Ages

30 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 30-45 years, women, overweight or obese class I, premenopausal, maintain current diet and exercise regimen

Exclusion criteria

  • pregnant or planning to become pregnant, currently have or history of cancer, heart disease, anemia, diabetes, depression

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems